The first immune checkpoint inhibitor (ICI) is ipilimumab, which is an antibody for cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and clinically effective in treating metastatic melanoma. This evidence concerns the gene CTLA4 and metastatic melanoma.